Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study-Reference-Cited by-同舟云学术

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Published:2019-04 Issue: Volume:30 Page:ii77
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Reinmuth N.,Cho B.C.,Lee K.H.,Luft A.,Ahn M.-J.,Schneider J.,Shepherd F.A.,Geater S.L.,Pápai-Székely Z.,Van Ngoc T.,Garassino M.C.,Liu F.,Clemett D.,Thiyagarajah P.,Ouwens M.,Scheuring U.,Peters S.,Rizvi N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_2/mdz094/28356007/mdz094.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer;Clinical Lung Cancer;2024-06

2. Prognostic implications and biological roles of EMT-related lncRNAs in lung squamous cell carcinoma: an in-depth analysis utilizing a novel prognostic signature and classification system;2023-10-04

3. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC;Journal of Thoracic Oncology;2023-01

4. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic;Journal of Thoracic Oncology;2020-07

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

;OncoTargets and Therapy;2020-07